CAO Pharmaceuticals

CAO Pharmaceuticals

Early Stage

An Oral and Non-toxic Cancer Treatment Option

An Oral and Non-toxic Cancer Treatment Option

Overview

Raised to Date: Raised: $1,000

Total Commitments ($USD)

Platform

Silicon Prairie Online

Start Date

05/01/2022

Close Date

04/24/2023

Min. Goal
$10,000
Max. Goal
$5,000,000
Min. Investment

$1,000

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$1,000,000

Rolling Commitments ($USD)

Status
Not Funded
Reporting Date

04/24/2023

Days Remaining
Not Funded
% of Min. Goal
Not Funded
% of Max. Goal
Not Funded
Likelihood of Max
Not Funded
Avg. Daily Raise

$3

Momentum
Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2015

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Webster, Texas

Business Type

Growth

CAO Pharmaceuticals is testing the waters on Silicon Prairie Online. The pharmaceutical company specializes in oral and non-toxic cancer treatment options using camptothecin (cpt). The company is testing a cpt derivative, CZ48, for toxicity and efficiency against cancers of the bladder, breast, kidney, lungs, ovary, pancreas, and prostate. Zhisong Cao founded CAO Pharmaceuticals in May 2015. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $5,000,000. The campaign proceeds will be used for the Phase 2 FDA trial, trial expenses, laboratory rental, utilities, expenses, and pipeline medication development.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-186,265

$-604,397

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$54,884

$78,415

Accounts Receivable

$0

$0

Total Assets

$2,662,118

$2,693,828

Short-Term Debt

$2,433

$2,878

Long-Term Debt

$0

$0

Total Liabilities

$2,433

$2,878

Financials as of: 05/01/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
CAO Pharmaceuticals on Silicon Prairie Online 2022
Platform: Silicon Prairie Online
Security Type: Equity - Common
Valuation: $1,000,000
Price per Share: $1.00

Follow company

Follow CAO Pharmaceuticals on Silicon Prairie Online 2022

Buy CAO Pharmaceuticals's Deal Report

Warning: according to the close date for this deal, CAO Pharmaceuticals may no longer be accepting investments.

CAO Pharmaceuticals Deal Report

Get KingsCrowd’s comprehensive report on CAO Pharmaceuticals including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether CAO Pharmaceuticals is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the CAO Pharmaceuticals deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge